US FDA punishes Ranbaxy again with another import alert

By Zachary Brennan

- Last updated on GMT

Ranbaxy was hit with another import alert from the FDA on Monday.
Ranbaxy was hit with another import alert from the FDA on Monday.

Related tags Fda import alert Current good manufacturing Generic drug

After finding cGMP violations at another Ranbaxy plant in India, the US FDA on Monday issued an import alert that effectively stops all of the plant’s drug shipments from entering the US.

The FDA issued the import alert​ for the Mohali, India-based facility after discovering cGMP (current good manufacturing practice) violations. The site is also now subject to terms of the consent decree​ that the company agreed to in January 2012. 

But the import alert for the Mohali site seems to have come as a surprise for the generic drug manufacturer. Ranbaxy spokeswoman Sharon Santacroce told In-Pharmatechnologist.com, “Concerning Mohali, we have so far not received any communication from the U.S. FDA on this subject.  We are seeking information from the US FDA in this regard​.”

FDA spokesman Stephen King assured us that the FDA notified Ranbaxy of the alert.

The US agency also noted that inspections from September and December 2012 identified significant cGMP (current good manufacturing) violations at the Mohali facility, including “failure to adequately investigate manufacturing problems and failure to establish adequate procedures to ensure manufacturing quality​.”

The import alert also may throw a wrench in the company’s plans to manufacture valsartan, the generic version of Novartis’ heart drug Diovan, according to industry blog Pharmalot.

The consent decree also calls for cGMP compliance at other Ranbaxy facilities in Paonta Sahib and Dewas, India, and it addresses data integrity issues at those two facilities. Ranbaxy’s Paonta Sahib and Dewas facilities have been on FDA import alert since 2008. Company spokesman Chuck Caprariello previously told us​ that the company retained cGMP consultants for the Paonta Sahib and Dewas sites to review its manufacturing practices there.


The violations at the Mohali site are the latest in a long list of manufacturing issues for Ranbaxy, which earlier this summer plead guilty to manufacturing adulterated drugs​, according to a settlement with the US DOJ (Department of Justice).

In addition, in December 2012, the company’s New Jersey-based plant experienced quality issues​ that caused it to halt Lipitor generic manufacturing.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...